Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Shares Outstanding (Weighted Average) (2016 - 2025)

OptimizeRx's Shares Outstanding (Weighted Average) history spans 14 years, with the latest figure at $18.5 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 1.47% year-over-year to $18.5 million; the TTM value through Sep 2025 reached $18.5 million, up 1.47%, while the annual FY2024 figure was $18.3 million, 6.82% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $18.5 million at OptimizeRx, roughly flat from $18.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $18.5 million in Q3 2025 and bottomed at $16.1 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $17.9 million (2022), against an average of $17.7 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) rose 18.38% in 2021 before it dropped 6.04% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $17.2 million in 2021, then grew by 3.23% to $17.8 million in 2022, then dropped by 3.71% to $17.1 million in 2023, then increased by 6.82% to $18.3 million in 2024, then grew by 1.24% to $18.5 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Shares Outstanding (Weighted Average) are $18.5 million (Q3 2025), $18.5 million (Q2 2025), and $18.5 million (Q1 2025).